[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 240 pages | ID: O533040D702BEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 32, 10, 1, 16, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Osteoarthritis Pain - Overview
Osteoarthritis Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteoarthritis Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteoarthritis Pain - Companies Involved in Therapeutics Development
Osteoarthritis Pain - Drug Profiles
Osteoarthritis Pain - Dormant Projects
Osteoarthritis Pain - Discontinued Products
Osteoarthritis Pain - Product Development Milestones
Featured News & Press Releases
Jul 18, 2022: OliPass moves forward to second stage of phase 2a trial for pain killer OLP-1002
Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
Jun 27, 2022: Virpax will pursue direct to OTC Pathway for Epoladerm for pain associated with osteoarthritis
Jun 01, 2022: AlzeCure's abstract on pain Project TrkA-NAM accepted for presentation at IASP 2022
May 02, 2022: Gordon Robert Alton, PhD joins BriOri BioTech as COO to develop patented topical formulation of Vioxx providing those suffering with osteoarthritis a long lasting non-opioid option for pain relief
Apr 20, 2022: Ampio provides regulatory update
Mar 22, 2022: Virpax completes all FDA-required pre-clinical studies for Epoladerm
Mar 09, 2022: BriOri BioTech granted patent for topical formulation of Vioxx
Mar 02, 2022: Xalud Therapeutics doses first patient in phase 2a trial of XT-150 for the treatment of facet joint osteoarthritis pain
Feb 15, 2022: BriOri BioTech granted patent for topical formulation of Rofecoxib
Dec 17, 2021: Xalud Therapeutics receives FDA Fast Track Designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee
Dec 07, 2021: Sorrento begins enrollment in phase 2 trial of resiniferatoxin (RTX) for the treatment of pain due to knee osteoarthritis (OA)
Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.
Oct 26, 2021: Paradigm: Phase 2 synovial fluid biomarker study update
Oct 14, 2021: Antibe Therapeutics provides update on Otenaproxesul and expanded drug pipeline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Osteoarthritis Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteoarthritis Pain - Pipeline by Acadia Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Achelios Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Adolore Biotherapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by AlzeCure Pharma AB, 2022
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Andros Pharmaceuticals Co Ltd, 2022
Osteoarthritis Pain - Pipeline by AntalGenics SL, 2022
Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Apimeds Inc, 2022
Osteoarthritis Pain - Pipeline by APT Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Aquilus Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by AstraZeneca Plc, 2022
Osteoarthritis Pain - Pipeline by Avecho Biotechnology Ltd, 2022
Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022
Osteoarthritis Pain - Pipeline by BioTissue Inc, 2022
Osteoarthritis Pain - Pipeline by BriOri BioTech Inc, 2022
Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, 2022
Osteoarthritis Pain - Pipeline by Chromocell Corp, 2022
Osteoarthritis Pain - Pipeline by Concentric Analgesics Inc, 2022
Osteoarthritis Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Eccogene (Shanghai) Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Eli Lilly and Co, 2022
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Ensign Pharmaceutical Inc, 2022
Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by EyePoint Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Futura Medical Plc, 2022
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, 2022
Osteoarthritis Pain - Pipeline by GSK plc, 2022
Osteoarthritis Pain - Pipeline by Levicept Ltd, 2022
Osteoarthritis Pain - Pipeline by Neumentum Inc, 2022
Osteoarthritis Pain - Pipeline by Novartis AG, 2022
Osteoarthritis Pain - Pipeline by Olatec Therapeutics LLC, 2022
Osteoarthritis Pain - Pipeline by OliPass Corporation, 2022
Osteoarthritis Pain - Pipeline by Overseas Pharmaceuticals Ltd, 2022
Osteoarthritis Pain - Pipeline by Pacira BioSciences Inc, 2022
Osteoarthritis Pain - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Osteoarthritis Pain - Pipeline by Peptide Logic LLC, 2022
Osteoarthritis Pain - Pipeline by Pfizer Inc, 2022
Osteoarthritis Pain - Pipeline by Pharmnovo AB, 2022
Osteoarthritis Pain - Pipeline by Pike Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Propella Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by ProteoThera Inc, 2022
Osteoarthritis Pain - Pipeline by Pure Green Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Q-State Biosciences Inc, 2022
Osteoarthritis Pain - Pipeline by RaQualia Pharma Inc, 2022
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by RHNanopharmacuticals LLC, 2022
Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, 2022
Osteoarthritis Pain - Pipeline by Sansho Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Saol Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Shanghai Leado Pharmaceutical Technology Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Shulov Innovative Science Ltd, 2022
Osteoarthritis Pain - Pipeline by Sorrento Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Symic Bio Inc, 2022
Osteoarthritis Pain - Pipeline by Techfields Pharma Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Tris Pharma Inc, 2022
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Virpax Pharmaceuticals Inc, 2022
Osteoarthritis Pain - Pipeline by Xalud Therapeutics Inc, 2022
Osteoarthritis Pain - Pipeline by Xgene Pharmaceutical Inc, 2022
Osteoarthritis Pain - Pipeline by Xintela AB, 2022
Osteoarthritis Pain - Pipeline by Yooyoung Pharm Co Ltd, 2022
Osteoarthritis Pain - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
Osteoarthritis Pain - Pipeline by ZYUS Life Sciences Inc, 2022
Osteoarthritis Pain - Dormant Projects, 2022
Osteoarthritis Pain - Discontinued Products, 2022
Osteoarthritis Pain - Discontinued Products, 2022 (Contd..1)

LIST OF FIGURES

Number of Products under Development for Osteoarthritis Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications